Utility of Amiodarone Pre-Treatment as a Facilitator of the Acute Success of Electrical Cardioversion in Persistent Atrial Fibrillation
Autor: | Xavier Viñolas, Josep M. Alegret, Miguel A. Arias, Victor Bazan, Pilar Valdovinos, Hernán Tajes, Raquel Palomares |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Pre treatment Male medicine.medical_specialty Time Factors Electric Countershock Amiodarone 030204 cardiovascular system & hematology Independent predictor Electrical cardioversion 03 medical and health sciences 0302 clinical medicine Heart Rate Recurrence Risk Factors Internal medicine Atrial Fibrillation medicine Humans Pharmacology (medical) Sinus rhythm Registries Class Ic Aged Retrospective Studies Pharmacology business.industry Atrial fibrillation General Medicine Middle Aged medicine.disease Antiarrhythmic drugs Lower incidence 030104 developmental biology Treatment Outcome Spain Persistent atrial fibrillation Cardiology Female Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents medicine.drug |
Zdroj: | CARDIOVASCULAR DRUGS AND THERAPY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Cardiovascular Drugs and Therapy r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol |
ISSN: | 0920-3206 1573-7241 |
Popis: | Purpose The usefulness and mechanisms of antiarrhythmic drug (AAD) pre-treatment as a facilitator of the acute success of electrical cardioversion (ECV) in atrial fibrillation (AF) remain controversial. We sought to analyze the role of AAD treatment with this purpose, differentiating its possible utility either facilitating the restoration of sinus rhythm (SR) or reducing immediate AF recurrences (IAFR). Methods We analyzed 2962 consecutive patients with persistent AF undergoing ECV prospectively included in 3 national registries. The acute success of ECV was indicated by the reversion to SR without presenting an IAFR (< 2 h). Results A total of 1410 patients (48%) received AAD treatment prior to ECV (80% amiodarone, 15% class Ic AAD, 2% other AAD). The rate of restoration of SR was similar between the patients treated with amiodarone (92%), class Ic AAD (91%) and who did not receive AAD pre-treatment (91%) (p = 0.92). However, those treated with amiodarone had fewer IAFR than those in the other two groups (amiodarone 3% vs class Ic 7% vs without treatment 6%; p = 0.002), so the ECV success rate was higher in the amiodarone group than in the other groups (amiodarone 89% vs Ic 84% vs without treatment 86%; p = 0.04). After adjusting for multiple variables, amiodarone remained as an independent predictor of a lower occurrence of IAFR (OR = 0.57; p = 0.01) and of a successful ECV (OR 1.37; p = 0.01). Conclusions For patients with persistent AF undergoing ECV, AAD has a neutral effect on the restoration of SR but amiodarone increases its effectiveness due to a lower incidence of IAFR. |
Databáze: | OpenAIRE |
Externí odkaz: |